there was no statstically significant difference of mir-155 expression in the specimens between non-small cell lung cancer patients and cancer-free individuals

The prognostic impact of miR-155 depends on histological subtype and nodal status in non-small cell lung cancer.

miR-155 could significantly inhibit the growth of human lung cancer 95D cells in vitro, which might be closely related to miR-155 induced G0/G1 phase arrest.

The expression levels of miR-21 and miR-155 were significantly higher in high-grade pulmonary neuroendocrine tumors than in carcinoid tumors.

High miR-155 expression is associated with lung cancer.

MiR-155 expression is associated with nodal status in resected stage III non-small cell lung cancer.

rs767649 A > T might contribute to the increased risk and poor prognosis of non-small cell lung cancer

we found that miR-155 promoted non-small cell lung carcinomas (NSCLC) cell proliferation through inhibition of FoxO1 and the subsequent increase of ROS generation. Our findings highlight miR-155/FoxO1/ROS axis as a novel therapeutic target for the inhibition of NSCLC growth.

Findings indicate that miR-21 and miR-155 promote the development of non-small cell lung carcinoma (NSCLC) in part by downregulating three tumor suppressor genes suppressor of cytokine signaling 1 protein (SOCS1), SOCS6, and PTEN.

Results show that microRNA-155 expression is increased in non-small cell lung cancer (NSCLC) tissue and independently associated with poor survival in NSCLC patients.

Study confirmed that miR-155 was upregulated in non-small cell lung cancer (NSCLC) and negatively regulated PDCD4 at both transcriptional and post-transcriptional levels. These results demonstrate the effects of miR-155 on multiplication and invasion by targeting PDCD4 in NSCLC suggesting that it plays a crucial role in NSCLC tumorigenesis

miR-155 mediated arsenic trioxide resistance by upregulating the Nrf2 signaling pathway, but downregulating cellular apoptosis in lung cancer cells.

The present meta-analysis demonstrated that miR-155 could be a potential biomarker for the detection of lung cancer but not an effective biomarker for predicting the outcomes of lung cancer.

Increased hsp70 promotes the synthesis and release of microRNA-155, which in turn leads to reduced expression of occludin protein in the blood-brain barrier, resulting in increased permeability of the blood-brain barrier and eventually causing lung cancer cells to metastasize into the brain

LncRNA MAGI2-AS3 Upregulates Cytokine Signaling 1 by Sponging miR-155 in Non-Small Cell lung cancer.